---
document_datetime: 2026-01-28 13:42:36
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vegzelma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: vegzelma-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.4348034
conversion_datetime: 2026-01-29 11:39:06.520195
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vegzelma

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | B.I.a.1 Change in the manufacturer of a | 14/11/2025                          | N/A                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000308860                     | starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.z Other variation - Accepted                                                                                                                                            |            |            |      |           |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------|
| PSUR / EMA/PSUR/0000274402            | - - In view of available data on hyaline occlusive glomerular microangiopathy reported in the literature, including in some cases a positive de-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between bevacizumab and hyaline occlusive glomerular microangiopathy is at least a reasonable possibility. The PRAC concluded that the product information of products containing bevacizumab should be amended accordingly. | 16/10/2025 | 18/12/2025 | SmPC | Variation |
| Article 61(3) / EMA/N/0000295472      | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representatives.                                                                                                                                                                                                                                                                                                                                               | 08/09/2025 |            | PL   |           |
| Variation type IB / EMA/VR/0000271859 | B.I.b.1 Change in the specification parameters and/or limits of an active                                                                                                                                                                                                                                                                                                                                                                                                       | 05/06/2025 | N/A        |      |           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                          | substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Change in the testing frequency of specification parameter, from routine testing to skip or periodic testing - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |                           |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|---------------------------|
| Variation type IB / EMA/VR/0000264760    | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - to apply editorial changes throughout Product Information as follows: - update of sections 4.4, 4.8 and 5.1 of the SmPC to align with Avastin Product Information; - VEGZELMA revised to Vegzelma according to Compilation of QRD decisions on stylistic matters in product Information; - addition of information regarding polysorbate according to Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'; - http://www.ema.europa.eu revised to https://www.ema.europa.eu according to the latest QRD template version 10.4; - addresses of manufacturers revised to align with Section 3.2.P.3.1. | 22/05/2025 | SmPC, Labelling and PL    |
| Variation type IA_IN / EMA/VR/0000258086 | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 26/03/2025 | SmPC, Annex II, Labelling |

<div style=\"page-break-after: always\"></div>

|                                  | A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted B.II.e.5.a Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - B.II.e.5.a.1 Change within the range of the currently approved pack sizes - Accepted   |            |            | and PL   |
|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|
| Article 61(3) / EMA/N/0000250376 | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representatives.                                                                                                                                                                                                                                                                                                                                                                            | 03/03/2025 | 03/06/2025 | PL       |